GB1524747A - Polypeptide - Google Patents

Polypeptide

Info

Publication number
GB1524747A
GB1524747A GB19327/76A GB1932776A GB1524747A GB 1524747 A GB1524747 A GB 1524747A GB 19327/76 A GB19327/76 A GB 19327/76A GB 1932776 A GB1932776 A GB 1932776A GB 1524747 A GB1524747 A GB 1524747A
Authority
GB
United Kingdom
Prior art keywords
tyr
leu
pro
arg
azgly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB19327/76A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Priority to GB19327/76A priority Critical patent/GB1524747A/en
Priority to IE808/77A priority patent/IE44426B1/en
Priority to ZA00772433A priority patent/ZA772433B/xx
Priority to US05/790,003 priority patent/US4100274A/en
Priority to NZ183931A priority patent/NZ183931A/xx
Priority to CA277,003A priority patent/CA1101844A/en
Priority to AU24681/77A priority patent/AU508025B2/en
Priority to HU77IE777A priority patent/HU179990B/hu
Priority to PL1977197889A priority patent/PL104362B1/pl
Priority to CS772980A priority patent/CS199673B2/cs
Priority to IL52014A priority patent/IL52014A/xx
Priority to DE2720245A priority patent/DE2720245C2/de
Priority to PL1977212706A priority patent/PL108860B1/pl
Priority to YU1172/77A priority patent/YU40672B/xx
Priority to CH578677A priority patent/CH627151A5/de
Priority to FI771480A priority patent/FI64139C/fi
Priority to SE7705432A priority patent/SE437837B/xx
Priority to FR7714262A priority patent/FR2351092A1/fr
Priority to NL7705130A priority patent/NL191793C/xx
Priority to NO771644A priority patent/NO147304C/no
Priority to BE177448A priority patent/BE854467A/xx
Priority to ES458691A priority patent/ES458691A1/es
Priority to SU772480485A priority patent/SU910116A3/ru
Priority to AT0335877A priority patent/AT379400B/de
Priority to DD77198869A priority patent/DD136738A5/xx
Priority to JP5418677A priority patent/JPS52136172A/ja
Priority to DK207977A priority patent/DK149596C/da
Publication of GB1524747A publication Critical patent/GB1524747A/en
Priority to CS79207A priority patent/CS199674B2/cs
Priority to AT0217979A priority patent/AT365562B/de
Priority to SE8007763A priority patent/SE437993B/sv
Priority to CH447281A priority patent/CH629475A5/de
Priority to NO822984A priority patent/NO149586C/no
Priority to FI830601A priority patent/FI75579C/fi
Priority to DK469983A priority patent/DK149272C/da
Priority to AT328084A priority patent/AT379596B/de
Priority to AT328184A priority patent/AT379597B/de
Priority to AT328584A priority patent/AT379600B/de
Priority to AT328384A priority patent/AT379818B/de
Priority to AT328284A priority patent/AT379598B/de
Priority to AT327984A priority patent/AT379595B/de
Priority to AT328484A priority patent/AT379599B/de
Priority to AT328684A priority patent/AT379601B/de
Priority to BG098123A priority patent/BG60740B2/bg
Priority to NL970002C priority patent/NL970002I2/nl
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
GB19327/76A 1976-05-11 1976-05-11 Polypeptide Expired GB1524747A (en)

Priority Applications (44)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide
IE808/77A IE44426B1 (en) 1976-05-11 1977-04-20 Polypeptide
ZA00772433A ZA772433B (en) 1976-05-11 1977-04-22 Polypeptide
US05/790,003 US4100274A (en) 1976-05-11 1977-04-22 Polypeptide
NZ183931A NZ183931A (en) 1976-05-11 1977-04-26 Polypeptide analogues of luteinising harmone releasing factor (lh-rf);pharmaceutical veterinary compositions
CA277,003A CA1101844A (en) 1976-05-11 1977-04-26 Polypeptide
AU24681/77A AU508025B2 (en) 1976-05-11 1977-04-28 Polypeptide
HU77IE777A HU179990B (en) 1976-05-11 1977-05-04 Process for preparing polypeptides
PL1977197889A PL104362B1 (pl) 1976-05-11 1977-05-05 Sposob wytwarzania polipeptydow
CS772980A CS199673B2 (en) 1976-05-11 1977-05-05 Method of producing polypeptides
IL52014A IL52014A (en) 1976-05-11 1977-05-05 Polypeptides having luliberin agonist properties
DE2720245A DE2720245C2 (de) 1976-05-11 1977-05-05 Peptide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Zusammensetzungen
PL1977212706A PL108860B1 (en) 1976-05-11 1977-05-05 Method of producing polypeptides
YU1172/77A YU40672B (en) 1976-05-11 1977-05-09 Process for obtaining a polypeptide of the formula glu-his-trp-ser-tyr-a-b-argo-pro-e-f
CH578677A CH627151A5 (https=) 1976-05-11 1977-05-09
FI771480A FI64139C (fi) 1976-05-11 1977-05-10 Polypeptid med inverkan pao djurens fortplantning
SE7705432A SE437837B (sv) 1976-05-11 1977-05-10 Polypeptid for att kontrollera och/eller forbettra reproduktionen hos djur jemte veteriner komposition innehallande nemnda polypeptid som aktiv bestandsdel
FR7714262A FR2351092A1 (fr) 1976-05-11 1977-05-10 Polypeptides ayant une activite agoniste de la luliberine
NL7705130A NL191793C (nl) 1976-05-11 1977-05-10 Werkwijze voor de bereiding van een polypeptide, en van een farmaceutisch of veterinair preparaat.
NO771644A NO147304C (no) 1976-05-11 1977-05-10 Polypeptid som har evnen til aa regulere og/eller oeke fruktbarheten hos dyr og/eller aa bedre ufruktbarhet hos menn og kvinner
BE177448A BE854467A (fr) 1976-05-11 1977-05-10 Polypeptides
ES458691A ES458691A1 (es) 1976-05-11 1977-05-11 Procedimiento para preparar polipeptidos.
SU772480485A SU910116A3 (ru) 1976-05-11 1977-05-11 Способ получени полипептидов или их солей
AT0335877A AT379400B (de) 1976-05-11 1977-05-11 Verfahren zur herstellung eines neuen polypeptids
DD77198869A DD136738A5 (de) 1976-05-11 1977-05-11 Verfahren zur herstellung neuer polypeptide
JP5418677A JPS52136172A (en) 1976-05-11 1977-05-11 Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect
DK207977A DK149596C (da) 1976-05-11 1977-05-11 Lh-rh-analoge nona- eller decapeptider, syreadditionssalte deraf og veterinaert middel til anvendelse til regulering og/eller forbedring af dyrs reproduktion
CS79207A CS199674B2 (cs) 1976-05-11 1979-01-09 Způsob výroby polypeptidů
AT0217979A AT365562B (de) 1976-05-11 1979-03-23 Verfahren zur herstellung eines neuen polypeptids
SE8007763A SE437993B (sv) 1976-05-11 1980-11-05 Sett att framstella en polypeptid med luliberin-agonist-egenskaper
CH447281A CH629475A5 (de) 1976-05-11 1981-07-07 Verfahren zur herstellung von polypeptiden.
NO822984A NO149586C (no) 1976-05-11 1982-09-03 Analogifremgangsmaate for fremstilling av terapeutisk aktive polypeptider
FI830601A FI75579C (fi) 1976-05-11 1983-02-23 Foerfarande foer framstaellning av terapeutiskt anvaendbar polypeptid.
DK469983A DK149272C (da) 1976-05-11 1983-10-12 Analogifremgangsmaade til fremstilling af lhrh-analoge nona- eller decapeptider eller farmaceutisk anvendelige syreadditionssalte deraf
AT328084A AT379596B (de) 1976-05-11 1984-10-15 Verfahren zur herstellung eines neuen polypeptids
AT328684A AT379601B (de) 1976-05-11 1984-10-15 Verfahren zur herstellung eines neuen polypeptids
AT328184A AT379597B (de) 1976-05-11 1984-10-15 Verfahren zur herstellung eines neuen polypeptids
AT328584A AT379600B (de) 1976-05-11 1984-10-15 Verfahren zur herstellung eines neuen polypeptids
AT328384A AT379818B (de) 1976-05-11 1984-10-15 Verfahren zur herstellung eines neuen polypeptids
AT328284A AT379598B (de) 1976-05-11 1984-10-15 Verfahren zur herstellung eines neuen polypeptids
AT327984A AT379595B (de) 1976-05-11 1984-10-15 Verfahren zur herstellung eines neuen polypeptids
AT328484A AT379599B (de) 1976-05-11 1984-10-15 Verfahren zur herstellung eines neuen polypeptids
BG098123A BG60740B2 (bg) 1976-05-11 1993-09-24 Полипептид
NL970002C NL970002I2 (nl) 1976-05-11 1997-01-15 Werkwijze voor de bereiding van een polypeptide, en van een farmaceutisch of veterinair preparaat.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (1)

Publication Number Publication Date
GB1524747A true GB1524747A (en) 1978-09-13

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
GB19327/76A Expired GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Country Status (27)

Country Link
US (1) US4100274A (https=)
JP (1) JPS52136172A (https=)
AT (2) AT379400B (https=)
AU (1) AU508025B2 (https=)
BE (1) BE854467A (https=)
BG (1) BG60740B2 (https=)
CA (1) CA1101844A (https=)
CH (2) CH627151A5 (https=)
CS (1) CS199673B2 (https=)
DD (1) DD136738A5 (https=)
DE (1) DE2720245C2 (https=)
DK (1) DK149596C (https=)
ES (1) ES458691A1 (https=)
FI (1) FI64139C (https=)
FR (1) FR2351092A1 (https=)
GB (1) GB1524747A (https=)
HU (1) HU179990B (https=)
IE (1) IE44426B1 (https=)
IL (1) IL52014A (https=)
NL (2) NL191793C (https=)
NO (2) NO147304C (https=)
NZ (1) NZ183931A (https=)
PL (2) PL104362B1 (https=)
SE (2) SE437837B (https=)
SU (1) SU910116A3 (https=)
YU (1) YU40672B (https=)
ZA (1) ZA772433B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897289B1 (en) 1999-05-20 2005-05-24 Lipotec, S.A. Peptide synthesis procedure in solid phase

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (https=) * 1988-12-20 1990-06-29
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
ES2077675T3 (es) * 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
HUT60139A (en) * 1989-07-07 1992-08-28 Endorecherche Inc Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
WO1991000732A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
JPH07506575A (ja) * 1992-05-21 1995-07-20 アンドルシェルシュ・インコーポレイテッド テストステロン５α−レダクターゼ活性の阻害剤
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US6448031B1 (en) 1996-06-13 2002-09-10 Itoham Foods Inc. Process for producing LH-RH derivatives
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
PL409579A1 (pl) 2001-02-19 2015-03-02 Novartis Ag Leczenie raka
PT1392313E (pt) 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR049938A1 (es) * 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
SI2415484T1 (sl) * 2004-09-17 2014-10-30 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
EP2119724A1 (en) 2005-05-03 2009-11-18 Novetide Ltd. Solid-phase process foor the preparation of goserelin
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP2009510073A (ja) 2005-09-27 2009-03-12 ノバルティス アクチエンゲゼルシャフト カルボキシアミン化合物およびその使用方法
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
MX2008014292A (es) 2006-05-09 2008-11-18 Novartis Ag Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
BRPI0807812A2 (pt) 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
JP2011506319A (ja) * 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
NZ588069A (en) 2008-03-26 2012-06-29 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN105727297A (zh) * 2008-11-28 2016-07-06 诺华股份有限公司 包含hsp90抑制剂和mtor抑制剂的药物组合
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
WO2011023677A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
WO2011029915A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
JP5466767B2 (ja) 2009-11-04 2014-04-09 ノバルティス アーゲー Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
CA2781218A1 (en) 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
KR20200144591A (ko) 2010-06-16 2020-12-29 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
BR112013031201A2 (pt) 2011-06-09 2017-01-31 Novartis Ag derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
JP2014518256A (ja) 2011-06-27 2014-07-28 ノバルティス アーゲー テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
JP5903499B2 (ja) 2011-12-22 2016-04-13 ノバルティス アーゲー ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
EP2794588A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
MX2014007732A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace.
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503518A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
BR112014015442A8 (pt) 2011-12-23 2017-07-04 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
JP6427097B2 (ja) 2012-06-15 2018-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌を処置するための組成物および該組成物を製造するための方法
KR20150042256A (ko) 2012-08-13 2015-04-20 노파르티스 아게 비장 티로신 키나제 (syk)의 억제제로서의 비시클릭 헤테로아릴 시클로알킬디아민 유도체
RS55764B1 (sr) 2012-10-02 2017-07-31 Gilead Sciences Inhibitori histonskih demetilaza
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
CA2901022C (en) 2013-02-27 2021-05-04 Epitherapeutics Aps Substituted pyridine compounds as inhibitors of histone demethylases
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
BR112016012141A2 (pt) 2014-01-15 2017-08-08 Novartis Ag "combinações farmacêuticas, uso das mesmas, e embalagem comercial"
MX2016012574A (es) 2014-03-28 2017-09-26 Calitor Sciences Llc Compuestos heteroarilo sustituidos y metodos de uso.
EP3126345A1 (en) 2014-03-31 2017-02-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
KR20160132496A (ko) 2014-04-03 2016-11-18 인빅터스 온콜로지 피비티. 엘티디. 초분자 조합 치료제
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
AU2020356605A1 (en) 2019-09-26 2022-04-14 S.I.S. Shulov Innovative Science Ltd. Anti-aging compositions and methods of use thereof
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (https=) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897289B1 (en) 1999-05-20 2005-05-24 Lipotec, S.A. Peptide synthesis procedure in solid phase

Also Published As

Publication number Publication date
CS199673B2 (en) 1980-07-31
NL970002I2 (nl) 1997-05-01
ATA335877A (de) 1985-05-15
DD136738A5 (de) 1979-07-25
PL108860B1 (en) 1980-05-31
FR2351092A1 (fr) 1977-12-09
JPS6113480B2 (https=) 1986-04-14
YU117277A (en) 1983-02-28
IE44426L (en) 1977-11-11
DE2720245A1 (de) 1977-11-24
NL970002I1 (nl) 1997-03-03
JPS52136172A (en) 1977-11-14
NL191793B (nl) 1996-04-01
NO771644L (no) 1977-11-14
SU910116A3 (ru) 1982-02-28
DK207977A (da) 1977-11-12
SE7705432L (sv) 1977-11-12
AT365562B (de) 1982-01-25
BG60740B2 (bg) 1996-01-31
NL7705130A (nl) 1977-11-15
FI64139C (fi) 1983-10-10
NO149586C (no) 1984-05-16
ZA772433B (en) 1978-03-29
NO149586B (no) 1984-02-06
FI771480A7 (https=) 1977-11-12
NO147304B (no) 1982-12-06
NL191793C (nl) 1996-08-02
DK149596C (da) 1987-01-05
US4100274A (en) 1978-07-11
FR2351092B1 (https=) 1980-02-22
AU2468177A (en) 1978-11-02
AU508025B2 (en) 1980-03-06
SE8007763L (sv) 1980-11-05
IE44426B1 (en) 1981-11-18
YU40672B (en) 1986-04-30
DK149596B (da) 1986-08-04
PL197889A1 (pl) 1978-02-13
HU179990B (en) 1983-01-28
NO147304C (no) 1983-03-16
AT379400B (de) 1985-12-27
CH629475A5 (de) 1982-04-30
PL104362B1 (pl) 1979-08-31
SE437837B (sv) 1985-03-18
BE854467A (fr) 1977-11-10
FI64139B (fi) 1983-06-30
NO822984L (no) 1977-11-14
DE2720245C2 (de) 1986-09-25
CH627151A5 (https=) 1981-12-31
CA1101844A (en) 1981-05-26
ATA217979A (de) 1981-06-15
NZ183931A (en) 1979-03-16
IL52014A (en) 1979-11-30
SE437993B (sv) 1985-03-25
ES458691A1 (es) 1978-08-16
IL52014A0 (en) 1977-07-31

Similar Documents

Publication Publication Date Title
GB1524747A (en) Polypeptide
GB1516947A (en) Hentricontapeptides
NISHIMURA et al. New method for removing the Sp-methoxybenzyl and St-butyl groups of cysteine residues with mercuric trifluoroacetate
KR0139632B1 (ko) 브라디키닌 길항 작용을 갖는 펩티드
GB1523623A (en) Activity and process for their manufacture
GB2091740A (en) C-terminal fragment of human chroionic gonadotropin
GB1498048A (en) Decapeptide amides
Manning et al. Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism
GB1527252A (en) Cyclization of peptides via cystine linkages
AU638735B2 (en) Peptides having bradykinin antagonist action
Katsoyannis The synthesis of the insulin chains and their combination to biologically active material
GB1528336A (en) Compounds compositions and methods of their use
KR840007569A (ko) Grf 유사체 펩티드의 제법
US4659691A (en) Novel cyclic Hexapeptide LHRH antagonists
GB1440859A (en) Vasopressin-type hormones and a method for their preparation
Sarantakis et al. Total synthesis of hypothalamic “somatostatin”
GB1526367A (en) Polypeptide
OTSUKA et al. Synthesis of an octadecapeptide and its 18-amide analog corresponding to the first eighteen amino acid residues of corticotropin (ACTH), and their biological activities
EP0212912A2 (en) Calcitonin analogs with C-therminal D-amino acid substituents
ES8507474A1 (es) Procedimiento para preparar ciclopeptidos
GB1294771A (en) Thyrocalcitonin derivative
GB1316545A (en) 1-alpha-aminoisobutyric acid-corticotropin peptides
DE3586936D1 (en) Peptide.
SHINODA Amino Acid Sequence of a Human Kappa Type Bence-Jones Protein: II. Chymotryptic Peptides and Sequence of Protein Ni
GB1523812A (en) Polypeptide

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
704A Declaration that licence is not available as of right for an excepted use (par. 4a/1977)
CTFF Supplementary protection certificate filed

Free format text: SPC/GB93/052, 930602

CTFG Supplementary protection certificate granted

Free format text: SPC/GB93/052, 931105, EXPIRES:20011130

CTFE Supplementary protection certificate entered into force

Free format text: SPC/GB93/052, 970421, EXPIRES:20011130

PE20 Patent expired after termination of 20 years

Effective date: 19970420

SPCE Supplementary protection certificate expired

Free format text: SPC/GB93/052, 20011130

SPCE Supplementary protection certificate expired

Free format text: SPC/GB93/052: 20011130